drugset

drugset / Trial / NCT04895449

Safety, Tolerability and Immunogenicity of the Candidate Vaccine MVA-SARS-2-ST Against COVID-19

NCT04895449 ↗

Phase 1 Completed 43 enrolled University Medical Center Hamburg-Eppendorf Clinical Trial Center North (CTC North GmbH & Co. KG) · collab German Center for Infection Research · collab IDT Biologika · collab Ludwig-Maximilians - University of Munich · collab Philipps University Marburg · collab

Non-randomizedParallel-groupOpen-labelPrevention

Summary

Multi-center phase Ib study to evaluate the Modified Vaccinia Virus Ankara (MVA) vaccine against SARS-CoV-2 in seronegative (Part A) and previously SARS-CoV-2-vaccinated individuals (Part B).

Timeline

Start: 2021-07-16
Primary completion: 2022-11-02
Completion: 2022-11-08

Publications

Grewe I, Friedrich M, Dieck ML, Spohn M, Ly ML, Krahling V, Mayer L, Mellinghoff SC, Rottstegge M, Kraemer R, Volz A, Becker S, Fathi A, Dahlke C, Weskamm LM, Addo MM. MVA-based SARS-CoV-2 vaccine candidates encoding different spike protein conformations induce distinct early transcriptional responses which may impact subsequent adaptive immunity. Front Immunol. 2024 Dec 19;15:1500615. doi: 10.3389/fimmu.2024.1500615. eCollection 2024.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	MVA-SARS-2-ST	Vaccine	1e+07 iu	Intramuscular
Subject	MVA-SARS-2-ST	Vaccine	5e+07 iu	Intramuscular
Subject	MVA-SARS-2-ST	Vaccine	1e+08 iu	Intramuscular

Indications